诺瓦瓦克斯（Novavax）股价上涨3.5%

Core Insights - Novavax's stock price increased by 3.5% following the signing of a vaccine development licensing agreement with Pfizer [1] Company Summary - Novavax has entered into a licensing agreement with Pfizer for vaccine development, which has positively impacted its stock performance [1] - The collaboration with Pfizer indicates a strategic move for Novavax in the competitive vaccine market [1] Industry Summary - The vaccine development sector continues to see significant partnerships, highlighting the importance of collaboration in advancing healthcare solutions [1] - The positive market reaction to the Novavax and Pfizer agreement reflects investor confidence in vaccine-related innovations [1]